Biofrontera AG
XETRA:B8F
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Biofrontera AG
XETRA:B8F
|
DE |
|
Fuji Corp (Miyagi)
TSE:7605
|
JP |
|
Allied Farmers Ltd
NZX:ALF
|
NZ |
|
M
|
Micro Friend Inc
KOSDAQ:147760
|
KR |
|
ZhuZhou QianJin Pharmaceutical Co Ltd
SSE:600479
|
CN |
|
Bens Creek Group PLC
LSE:BEN
|
UK |
|
Arjo AB (publ)
STO:ARJO B
|
SE |
|
Silicius Real Estate SOCIMI SA
MAD:YSIL
|
ES |
|
T
|
The Born Korea Co Ltd
KRX:475560
|
KR |
|
N
|
Nanogroup SA
WSE:NNG
|
PL |
|
Gear4music Holdings PLC
LSE:G4M
|
UK |
Biofrontera AG
Biofrontera AG engages in the development, sale and distribution of dermatological drugs and medical cosmetics for the care, protection and treatment of the skin. The company is headquartered in Leverkusen, Nordrhein-Westfalen and currently employs 167 full-time employees. The company went IPO on 2006-10-30. The firm develops drugs and medicinal cosmetics for the treatment of skin diseases and regenerative care of damaged skin. Its portfolio includes: Ameluz, for photodynamic therapy (PDT) of actinic keratoses, and under development for other types of skin cancer and warts; PDT lamp BF-RhodoLED, used after the Ameluz treatment to eliminate infected cells; and Belixos, a dermatological cream with herbal ingredients for the care of itching, inflamed and flaky skin and conditions such as insect bites, burns, neurodermatitis and psoriasis. The firm is also engaged in clinical development of two drug candidates: BF-derm1, a tablet with inhibitor blocking the synthesis of histamine in cells, a cause of allergic reactions; and BF1, a selective serotonin receptor to prevent migraines. The firm operates five wholly owned subsidiaries, notably Biofrontera Inc in the United States. Its main shareholder is MM Familien KG.
Biofrontera AG engages in the development, sale and distribution of dermatological drugs and medical cosmetics for the care, protection and treatment of the skin. The company is headquartered in Leverkusen, Nordrhein-Westfalen and currently employs 167 full-time employees. The company went IPO on 2006-10-30. The firm develops drugs and medicinal cosmetics for the treatment of skin diseases and regenerative care of damaged skin. Its portfolio includes: Ameluz, for photodynamic therapy (PDT) of actinic keratoses, and under development for other types of skin cancer and warts; PDT lamp BF-RhodoLED, used after the Ameluz treatment to eliminate infected cells; and Belixos, a dermatological cream with herbal ingredients for the care of itching, inflamed and flaky skin and conditions such as insect bites, burns, neurodermatitis and psoriasis. The firm is also engaged in clinical development of two drug candidates: BF-derm1, a tablet with inhibitor blocking the synthesis of histamine in cells, a cause of allergic reactions; and BF1, a selective serotonin receptor to prevent migraines. The firm operates five wholly owned subsidiaries, notably Biofrontera Inc in the United States. Its main shareholder is MM Familien KG.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
